Exagen Inc. cash flow to debt ratio of -53.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Exagen Inc.'s free cash flow has decreased 3.42% from $-13.79M last year to $-14.27M, signaling decreasing performance

Exagen Inc.'s debt to equity ratio is 2.09, which means that the company's assets are unhealthy financed, signaling financial risk.

Exagen Inc.'s debt has decreased relative to shareholder equity from 2.43 last year to 2.09 today, signaling strengthened financials

Exagen Inc. has a net cash position, so leverage is healthy.

Exagen Inc.'s interest coverage ratio is -2.58, which means that the company struggles to meet interest obligations, signaling financial risk.

Exagen Inc.'s profit margin has increased (-2.06%) in the last year from -27.17% to -26.61%, signaling increasing performance

Exagen Inc.'s short-term assets of $48.89M exceed its short-term liabilities of $14.16M

Exagen Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Exagen Inc.'s return on equity of -121.62%, is lower than 15.00%, indicating bad performance

Exagen Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Exagen Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Exagen Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Exagen Inc. has negative free cash flow, indicating cash burn

Exagen Inc.'s yearly earnings has decreased 31.99% since last year from $-15.12M to $-19.95M, signaling decreasing performance

Exagen Inc.'s yearly revenue has increased 19.65% since last year from $55.64M to $66.58M, signaling increasing performance

ROIC -32.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Exagen Inc.'s 3-year revenue CAGR of 13.47% is positive, indicating growing revenue over the past 3 years

Exagen Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Exagen Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Exagen Inc. has insufficient data to evaluate this check.

Exagen Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Exagen Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Exagen Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Exagen Inc. is overvalued relative to its fair value price of -25.98 based on Earnings Fair Value model

Exagen Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Exagen Inc. has a price-to-book ratio of 13.14x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Exagen Inc. has a price-to-sales ratio of 2.26x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue